期刊文献+

2种喹诺酮药物单用及联合氨苄西林或卡那霉素对猪源沙门菌耐药突变选择窗的研究 被引量:2

Study on Mutant Selection Window of two Fluoroquinolones alone and combination with Ampicillin or Kanamycin against SalmonellaIsolated from Swine
下载PDF
导出
摘要 为探讨联合用药对猪沙门菌耐药突变选择窗的影响,采用琼脂二倍稀释法测定环丙沙星、左氧沙星及其联合氨苄西林和卡那霉素对56株临床分离的猪源沙门菌的最低抑菌浓度(MIC)、耐药变异浓度(MPC)、耐药指数(SI),并进行统计学分析。结果显示,环丙沙星联合氨苄西林和卡那霉素后其耐药变异浓度(MPC)降低到2mg/L和1mg/L,SI分别下降了4倍和8倍;左氧沙星联合氨苄西林和卡那霉素MPC降低到1mg/L和0.5mg/L,SI分别下降了2倍和4倍;且两种药物与卡那霉素联合能完全关闭其突变选择窗(MSW)。本研究表明,环丙沙星、左氧沙星联合氨苄西林和卡那霉素能够缩小甚至关闭其单药的MSW,防止耐药的产生。 To study the effect of antibiotics combination on the mutant selection window (MSW) of salmonella isolated from swine. The MIC of ciprofloxacin (CIP), levofloxacin (LVF), ampicillin (AMP) and kanamycin(KAN) and the mutant prevention concentration (MPC) both sole and combined were de- termined by the method of agar plates dilution method, and the value of SI (selection index : MPC/M IC) was acquired. SPSS statistics software was used to analyze the data. The results showed that after com- bined with ampicillin and kanamycin, the MPC of ciprofloxacin was reduced to 2 mg/and 1 mg/L, and the value of SI decreased by 4- and 8-fold respectively. The MPC of levofloxacin was reduced to 1 mg/L and 0. 5 mg/L and the SI decreased by 2- and 4-fold. Compared with sole treatment, CIP and LVF combined with other two antibiotics can decrease MPC and SI of antibiotics alone and restrain the drug-resistant mutants.
出处 《中国兽医杂志》 CAS 北大核心 2013年第8期32-35,共4页 Chinese Journal of Veterinary Medicine
关键词 猪沙门菌 耐药突变选择窗 防耐药变异浓度 联合用药 Salmonella mutant selection window MPC drug combination
  • 相关文献

参考文献10

  • 1Zhao X, Drlica K. Restricting the selection of antibiotic-resist- ant mutants a general strategy derived from fluoroquinolone studies[J]. Clin Infect Dis,2001,33 (Suppl 3) :147-156.
  • 2Drlica K,Zhao X. Mutant Selection Window Hypothesis Upda- ted[J]. Clin Infect Dis,2007, 44(5) :681-688.
  • 3Zhao X,Drlica K. A unified anti-mutant dosing strategy[J]. Antimicrob Chemother, 2008,62(3) : 434-436.
  • 4崔俊昌,刘又宁,王睿,梁蓓蓓,裴斐,郑专杰.4种氟喹诺酮类药物对金黄色葡萄球菌的防耐药变异浓度[J].中华医学杂志,2004,84(22):1863-1866. 被引量:34
  • 5Drlica K. The mutant selection concentration and antimicrobial resistance[J]. J Antimicmb Chemother, 2003,52 (1) : 11-17.
  • 6李朝霞,刘又宁,王睿,童卫杭,程仕虎.左氧氟沙星联合万古霉素缩小金黄色葡萄球菌耐药突变选择窗的初步研究[J].中国临床药理学与治疗学,2007,12(8):911-914. 被引量:32
  • 7宋秀杰,张雷,鞠红梅,王睿,刘又宁.左氧沙星单用及与磷霉素联用对金黄色葡萄球菌的防耐药突变浓度研究[J].中国临床药理学杂志,2010,26(12):888-892. 被引量:10
  • 8Firsov A A,Lubenko I Y,Smirnova M V,et al. Enrichment of Fluoroquinolone- resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window[J]. Antimicrob A- gents Chemother,2008, 52(6) : 1924-1928.
  • 9Scaglione F, Mouton J W, Mattina R, et al. Pharmacodynam- ies of Levofloxaein and Ciprofloxacin in a Murine Pneumonia Model:Peak Coneentration/MIC versus area underthe Curve/ MIC ratios[J]. Antimicrob Agents Chemother, 200a, 47 (9) : 2749-2755.
  • 10Drago L, De Vecchi E, Nieola L, et al. In vitro evaluation of antibiotic.s combinations for empirical therapy of suspected methicillin-resistant Staphylococcus aureus severe respiratory infections [J]. Antimicrob Chemother , 2005,56(2) 353-359.

二级参考文献22

  • 1刘杨,吴菊芳,萧正伦,盛瑞媛,吕晓菊,陈燕,张婴元.1031例患者应用去甲万古霉素不良反应观察[J].中华内科杂志,2004,43(11):815-819. 被引量:46
  • 2段利生,虎安定.喹诺酮类药物不良反应特征综述[J].中国药事,2005,19(2):117-119. 被引量:19
  • 3Wilcox MH.Future gazing in the management of multiply drug-resistant gram-positive infection[J].J Infection,2009 ; 59 (Suppl.1):S75 -S80.
  • 4Anderson DJ,Kaye KS,Chen LF.Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection:A multi -center matched outcomes study[J].PLoS One,2009 ;4:8305.
  • 5European Antimicrobial Resistance Surveillance System Annual Report.2004.Available at:Accessed September 9,2008.
  • 6Lutz L,Machado A,Kuplich N,et al.Clinical failure of vancomycin treatment of Staphylococcus aureus infection in A Tertiary Care Hespital in-seuthem Brazil[J].Braz J Infect Dis,2003;7:224-228.
  • 7Olofsson SK,Cars O.Optimizing drag exposure to minimize selection of antibiotic resistance[J].Antibiotic Dos Res/stance,2007 ;45(Suppl.2) S129-S136.
  • 8National Commettee for Clinical Laboratory Standards[S].2002:99-103.
  • 9Zhao X,Eisner W,Ped-Rosenthal N.et al.Mutant prevention concentration of garenoxacin(BMS一284756)for ciprotloxacinsusceptible or-resistant Staphylococcus aureus[J].Antimicrob.Agents Chemother,2003;47:1023-1027.
  • 10Odica K.A strategy for fighting antibiotic resistance[J].ASM News,2001;67:272-331.

共引文献66

同被引文献14

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部